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ABSTRACT
Rationale: Current techniques for monitoring patients
for apnoea suffer from significant limitations. These
include insufficient availability to meet diagnostic
needs, cost, accuracy of results in the presence of
artefacts and difficulty of use in unsupervised
conditions.
Objectives: We created and clinically tested a novel
miniature medical device that targets overcoming these
limitations.
Methods: We studied 20 healthy control participants
and 10 patients who had been referred for sleep
apnoea diagnosis. The performances of the new
system and also of the Food and Drug Administration
(FDA) approved SOMNO clinical system, conventionally
used for sleep apnoea diagnosis were evaluated under
the same conditions. Both systems were tested during
a normal night of sleep in controls and patients. Their
performances were quantified in terms of detection of
apnoea and hypopnoea in individual 10 s epochs,
which were compared with scoring of signals by a
blinded clinician.
Main results: For spontaneous apnoeas during
natural sleep and considering the clinician scorer as
the gold standard, the new wearable apnoea detection
device had 88.6% sensitivity and 99.6% specificity. In
comparison the SOMNO system had 14.3% sensitivity
and 99.3% specificity. The novel device had been
specifically designed to detect apnoea, but if apnoea
and hypopnoea during sleep were both considered in
the assessment, the sensitivity and specificity were
77.1% and 99.7%, respectively, versus 54% and
98.5%, respectively, for the SOMNO.
Conclusions: The performance of the novel device
compares very well to the scoring by an experienced
clinician even in the presence of breathing artefacts, in
this small pilot study. This can potentially make it a
real solution for apnoea home monitoring.
INTRODUCTION
Apnoea may occur acutely in the context of
infectious, respiratory, cardiac and neurological
disease1–5; may be caused by medication6–8;
and, on occasion, death may be averted with
urgent intervention.1 6 9–11 Apnoea may also
occur recurrently either as a comorbidity in
chronic conditions including asthma, gastro-
oesophageal reﬂux, neuromuscular disorders
and diabetes,12–16 or on its own in sleep
apnoea syndrome.17–27
The importance of monitoring and quanti-
fying apnoeas is widely acknowledged.
Apnoeas are one of two leading causes of
sudden death in epilepsy (SUDEP), which in
the UK alone affects more people than cot
death and AIDS put together.28 29 Apnoeas
are also known to be a major problem due
to their potentially disastrous consequences
in anaesthesia recovery rooms.30 31 Sleep
apnoea may affect between 2% and 10% of
the adult population24 and 1% to 3% of the
paediatric population,18 and is heavily under-
diagnosed.19 The indirect medical costs of
underdiagnosed adult patients, in the years
preceding the diagnosis, is estimated to
increase by up to twofold, even after correct-
ing for chronic disease status.22 23 This,
added to the potential social consequences
in the form of accidents, increased morbidity
and impact on work efﬁciency, makes the
condition a major public health issue.24
Currently existing techniques for monitor-
ing and quantiﬁcation of apnoeas are not sat-
isfactory. In sleep apnoea diagnosis,
polysomnography is the gold standard; but
the lack of sleep laboratories, sleep specialists
Strengths and limitations of this study
▪ We present the smallest, least intrusive technol-
ogy to automatically detect apnoeas/hypopnoeas.
▪ Performance characterisation in signals with and
without artefacts, showing excellent agreement
with expert—60 000 epochs assessed in con-
trols and patients.
▪ Sensitivity six times better than a state-of-the-art
commercial system and excellent scoring in
terms of user acceptance.
▪ The size of the study is limited. This is, however,
justified by the fact that it was an initial pilot
study to prove the strength of this novel technol-
ogy to detect individual events even in the pres-
ence of artefacts (study goals of 95% CIs for
sensitivity and specificity values).
▪ The technology is still not optimised for hypop-
noea detection.
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and the associated cost either make it difﬁcult for the
family physician to conﬁrm the suspicion, or delay diag-
nosis.25 The importance of the problem has led
Medicare and Medicaid in the USA to recently authorise
payment of treatment for adults diagnosed with
unattended home sleep monitoring devices.24
Unfortunately, existing home monitoring devices suffer
from one or several of the following limitations: the
sensors can be difﬁcult to place resulting in unaccept-
able recordings; they still require considerable specialist
time in order to interpret the results; automatic inter-
pretation is very inaccurate mainly due to the inability to
deal with artefacts; and sensors can be cumbersome or
intrusive, affecting the quality of sleep.26–27
Furthermore, there is no portable apnoea monitoring
system that can detect apnoeas with high enough sensi-
tivity and speciﬁcity in real time to potentially be used to
alert carers of life-threatening situations due to acute
apnoea, which can occur in the context of other clinical
scenarios such as epilepsy or in anaesthesia. In these
scenarios also, the alternative of relying on devices that
might be able to detect the sequelae of apnoea (eg,
pulse oximeters to detect hypoxaemia or heart rate
monitors to detect bradycardia) might result in fatal
consequences due to a delayed response to the apnoea.
We present the results of the ﬁrst clinical study of a
new wearable apnoea detection device (WADD) speciﬁc-
ally designed to overcome the limitations of all other
existing technologies.
METHODS
Device
We determined that the strongest externally detectable
signal related to breathing corresponded to turbulence
in the trachea. This signal was detected with a customised
acoustic chamber that optimised the signal transmission.
The signal detected by the sensor has components corre-
sponding to both the wanted ‘signal’ (breathing) and
undesired ‘noise’ caused by artefacts (cardiac signal,
external noise (eg speech, music and wind), movement
causing rubbing against the sensor and electromagnetic
interference). A novel signal processing algorithm was
developed to differentiate ‘signal’ from ‘noise’. The algo-
rithm evaluates the temporal and frequency character-
istics of the signal obtained from the sensor. Over 15
different features are analysed with parametric functions
that dynamically adapt over time, to compensate for
changes in the participant and the environment. No pre-
calibration or participant speciﬁc knowledge or modiﬁca-
tion is needed for the sensor or the signal processing
algorithm.32–34 Part of the algorithm was implemented
on hardware and incorporated into the sensor. This
reduces the amount of data that is needed for wireless
transmission and consequently the amount of power
required from the battery; hence the small size of the
device. The wireless receiver and the remaining part of
the algorithm were run on a laptop computer.
The WADD we used in the study was wireless, mea-
sured 3.74×2.4×2.1 cm weighed 17 g and was ﬁxed to the
skin on the neck with hydrocolloid colostomy adhesive
patches of approximately 4 cm diameter (Boots, UK).
The preferred location was over the trachea, halfway
between the lower margin of the thyroid cartilage and
the suprasternal notch (ﬁgure 1(A)). If the skin in that
Figure 1 (A) wearable apnoea detection device (WADD)
worn by one of the investigators. (B) Participant wearing an
existing state of the art ambulatory apnoea monitoring system
(SOMNO), comprising finger oximetry; oronasal flow sensors;
thoracic and abdominal expansion bands; and ECG.
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location was loose, as was common in participants above
40 years of age, the device was placed anterolaterally,
anterior to the sternomastoid muscle. The device was
left in place overnight, for approximately 14 h.
Participants
The study was conducted in a sleep study room of the
National Hospital for Neurology and Neurosurgery
(UK). We studied 20 healthy controls and 10 patients, as
they were sequentially admitted for diagnostic monitor-
ing of sleep-related disorders of breathing, because
these were likely to have spontaneous apnoea events.
The patients and controls were not matched. Patients
also had a variety of neurological conditions, including
epilepsy, dementia, neuropathy and motor neuron
disease. The reasons to recruit patients who had been
referred for diagnosis of possible sleep-related disorders
of breathing, as opposed to those who had been already
diagnosed, were twofold. First, the purpose of this study
was not to evaluate the WADD for sleep apnoea diagno-
sis, but rather to evaluate its ability to detect individual
events during controlled conditions to assess the robust-
ness to artefact rejection and also during spontaneous
sleep. Good performance on individual event identiﬁca-
tion would, however, be expected to translate in a good
performance in the context of the different clinical
applications. Second, non-diagnosed patients were
recruited because studying diagnosed individuals would
have involved either delay or interruption of their treat-
ment. The decision on the number of patients was
based on obtaining a large enough number of events
that would lead to the study goals of 95% CIs for sensi-
tivity and speciﬁcity values (based on clinical experience
on the minimum number of apnoea events that would
be expected per subject referred for sleep apnoea diag-
nosis, per night). A larger number of controls were
included to be able to assess speciﬁcity among those
who were most likely to be disease free, and also in the
presence of artefacts. The patient group comprised
2 females and 8 males with: a median age of 44.5 years
of age (range 25–82); a median weight of 74 kg (range
41–187); a median height of 177 cm (range 160–188); a
median body mass index (BMI) of 23 kg/cm2 (range
17–61); and a median neck circumference of 40 cm
(range 30–43). The control group comprised 3 females
and 17 males with: a median age of 33.5 years of age
(range 23–63); a median weight of 81.5 kg (range
60–120); a median height of 176 cm (range 145–185); a
median BMI of 26.5 kg/cm2 (range 20–36); and a
median neck circumference of 38 cm (range 34–48).
Overall, 40% of the participants were overweight and
24% were obese.
Procedure
All participants also had simultaneous, clinically standard
respiratory monitoring comprising: ﬁnger oximetry; oro-
nasal airﬂow sensors; thoracic and abdominal expansion
bands; and ECG; using the SOMNO polysomnography
system (SOMNOscreen RC kombi. SOMNO Medics,
Germany) (ﬁgure 1(B)). Additionally, to further facilitate
expert interpretation of polysomnography data, a second
pulse oximeter (Pulsox-300i, Konica Minolta, Japan) was
attached to the free hand. After attachment of the WADD
and the SOMNOmedics polysomnography system,
control participants participated in a series of exercises,
comprising:
Normal breathing for 5 min.
T1. Shallow breathing for 5 min.
T2. Normal breathing for 45 s alternating with 15 s
instructed breath holds for 5 min.
T3. Normal breathing for 30 s alternating with 30 s
instructed breath holds for 10 min.
T4. As in 3 but with loud music in the background.
T5. Normal breathing while walking for 5 min.
T6. Normal breathing for 30 s alternating with 30 s
instructed breath holds while lying prone for 5 min.
These exercises were designed to be representative of
the worse case of artefact situations affecting the WADD
following previous, very exhaustive, laboratory-based
research and testing. Following the exercises participants
were allowed to prepare for sleep and were left undis-
turbed overnight.
Data analysis
The breathing exercises data were analysed by the auto-
mated WADD software and the automated SOMNO soft-
ware. Instructed apnoeas were considered to be the
‘true events’. The last 6 h of sleep were blindly analysed
by the automated WADD software, the automated
SOMNO software and by the experienced clinician who
reviewed the raw signals from all SOMNO sensors, and
had no knowledge about how WADD had been designed
or worked. The reason to evaluate the last 6 h of sleep
was to try to keep the same amount of sleep data in as
many participants as possible in order to prevent biasing
of the results. The pulse oximeter was also used by the
clinician to support the diagnostic decisions and also
individual event classiﬁcation mostly in those cases in
which the signals from the other SOMNO pulse oxim-
eter were corrupted by artefacts. After the separate clas-
siﬁcation of WADD and SOMNO data, a further
investigator compared the results.
The breathing exercises data were analysed in 15 s
epochs because this was the shortest duration of an
instructed apnoea. The sleep data were analysed in 10 s
epochs.
Two assessments were carried out of the sleep data. In
the ﬁrst assessment there was no preassumption of a
gold standard, and the three systems (WADD, SOMNO
and expert marker) were put under test and treated
indistinctively. An epoch would be classiﬁed as true posi-
tive apnoea or true positive hypopnoea if at least two out
of the three systems concurred on the classiﬁcation. In
the second assessment the ﬁnal classiﬁcation of these
epochs would be that of the expert marker or, in other
words, the expert marker was considered to be the gold
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standard deciding, and the performances of SOMNO
and WADD system were evaluated. The SOMNO was
evaluated as well as the WADD, as there is little or no
quantitative information about the accuracy of auto-
mated polysomnography systems.
In both assessments epochs could be classiﬁed as:
A. True positive apnoea (cessation of breathing signal,
with correspondent absence of respiratory airﬂow).
B. True positive hypopnoea (over 50% reduction in oro-
nasal signal and in thoracoabdominal movement
together with over 2% decrease in oxygen
saturation).
C. False positive hypopnoea (if a system had classiﬁed a
breathing epoch as a hypopnoea).
D. False positive apnoea (if a system had classiﬁed a
breathing epoch as an apnoea).
E. False classiﬁcation apnoea as hypopnoea (if a system
had classiﬁed an apnoea epoch as hypopnoea).
F. False classiﬁcation hypopnoea as apnoea (if a system
had classiﬁed hypopnoea as apnoea).
G. False negative apnoea (if a system had classiﬁed an
apnoea as breathing).
H. False negative hypopnoea (if a system had classiﬁed a
hypopnoea as breathing).
The breathing exercises data were analysed in the
same way, but the instructed apnoeas and breathing sec-
tions were considered the absolute truth and hence
there was no independent expert review.
The performances of the three systems were evaluated
using the following metrics:
Sensitivity ¼ (TP)=(TPþ FN)
Specificity ¼ (FP)=(TNþ FP)
(TP=true positive, TN=true negative, FP=false positive,
FN=false negative).
The analysis was carried out assuming that all apnoea
events were independent, since it was observed that the
characteristics of the breathing signal changed as much
within the same participant (depending on timing, pos-
ition, external artefacts, etc), as between different partici-
pants. This was further veriﬁed by taking three random
10 min sections of the sensed breathing signals in the 30
different participants and obtaining the different correl-
ation coefﬁcients (2700 in total). The maximum correl-
ation coefﬁcient obtained from signals within the same
participant was 0.05. The maximum correlation coefﬁ-
cient obtained from different subjects was 0.067.
For each of the two assessments (ie, not presuming a
gold standard and considering the expert to be the gold
standard), two different analyses were carried out. First,
only apnoeas were considered to be true positives.
Hence any hypopnoea would be regarded as breathing
(true negative); False classiﬁcation of hypopnoeas as
apnoeas were reclassiﬁed as false positives; and false clas-
siﬁcation of apnoeas as hypopnoeas were re-classiﬁed as
false negatives. Second, apnoeas and hypopnoeas were
considered indistinctively, and hence true events of both
varieties would be also considered together.
These two analyses were carried out as they would be
relevant to different clinical scenarios. For example, high
sensitivity for detecting apnoea would be crucial for iden-
tiﬁcation of sudden apnoea if monitoring those with epi-
lepsy; whereas for diagnosis of sleep-related breathing
dysfunction, which generally relies on the Apnoea
Hypopnoea Index, the differentiation between apnoea
and hypopnoea might be clinically less important.
RESULTS
Breathing exercises data
Data were available in 3956 15s epochs for the controls
performing the breathing exercises (132 in total).
Table 1 summarises the performance of WADD and
SOMNO in the seven breathing exercises. Figure 2 illus-
trates examples of the signals obtained from the differ-
ent sensors. Table 1 is divided in three parts. Part (a)
and (b) quantify performance considering different
scenarios for wrongly classiﬁed hypopnoeas. Although
the real events were apnoeas, both systems had the
ability to indicate hypopnoeas too. This resulted in some
real apnoea and breathing epochs being wrongly
marked as hypopnoeas. To account for these, table 1
(A) shows the sensitivity and speciﬁcity when only
apnoeas are considered as events (ie, hypopnoeas would
be regarded as breathing). In part (B) of the table
hypopnoeas and apnoeas are indistinctively considered.
Part (C) illustrates the total number of epochs that fall
into a speciﬁc classiﬁcation for both systems. The com-
bined sensitivity and speciﬁcity for all the exercises
across all the participants for the WADD was 97.7% and
99.6% (considering hypopnoeas as breathing); or 99.2%
and 99.5% (considering hypopnoeas as events). With
the same criteria the sensitivity and speciﬁcity for the
SOMNO was only 37.8% sensitivity, 96.5% speciﬁcity; or
62.8% sensitivity, 90.5% speciﬁcity.
Sleep data
For the sleep data 62727 10s epochs were analysed, in
total, 34 true apnoea epochs and 40 true hypopnoea
epochs were identiﬁed for the controls (36 and 37 if the
clinician scorer was considered to be the gold standard);
and 312 apnoea epochs and 181 hypopnoea epochs for
the patients (342 and 200 if the clinician scorer was con-
sidered to be the gold standard). The average number
of apnoea epochs for the patient group throughout the
night was 32. All patients had episodes of apnoea or
hypopnoea. There were only two patients who did not
have any episode of apnoea. For one control, only 3.2 h
of data were recorded, because of an ICT error. For one
patient, only 3 h were analysed as more than one
SOMNO sensor including the nasal cannula and the
pulse oximeters detached prematurely. The results in
terms of sensitivity and speciﬁcity for the control group,
patient group and overall are presented in table 2.
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Table 2 is divided in four parts: the ﬁrst and second
evaluate the performance for apnoea and apnoea/
hypopnoea combined detection respectively without
assuming a gold standard (ie, the consensus of the
majority determines a true event); and the third and
fourth parts present the same evaluation but considering
the expert as the gold standard.
The WADD also had the added feature of being able
to differentiate between central and obstructive apnoea.
90% of the central apnoeas were rightly marked as
central. 96% were rightly marked as obstructive.
Approximately 60% of the total apnoeas were obstruct-
ive in origin.
Device comfort
After the overnight study, the devices were detached and
the participants scored the comfort of the devices and
quality of sleep (rating 1–5, with 5 representing
maximum comfort and quality). Skin irritation caused
by the WADD’s adhesive was also rated from 1 to 5
(5 representing no irritation, 4 mild transient, redness
and 1 severe irritation). The median rating for WADD
comfort was 5 (range 4–5). The median rating for
SOMNO comfort was 3 (range 1–5 for controls and 2–5
for patients). The median rating for irritation caused by
the WADD plaster on the neck was 5 (range 5–5 for con-
trols and 4–5 for patients).
DISCUSSION
Main findings
WADD had very high sensitivity and speciﬁcity for detect-
ing apnoea in 15 s epochs in a series of breathing and
breath-holding exercises in a variety of conditions,
including the presence of external background noise,
movement and posture. The tolerability of WADD was
Table 1 Summary of performance for the WADD and SOMNO across the seven breathing exercises (as detailed in procedure)
Exercise
Sensitivity (%) Specificity (%)
WADD SOMNO WADD SOMNO
(A) WADD versus SOMNO performance in instructed exercises with hypopnoeas NOT considered as events
T1 NA NA 100 99.2
T2 NA NA 100 90.6
T3 94.6 38 99 96.9
T4 98.9 38.8 99.7 94.5
T5 99.2 31.4 99.2 99.7
T6 NA NA 100 96.5
T7 94.2 48.2 98.5 99
Total 97.7 37.8 99.6 96.5
(B) WADD versus SOMNO performance in instructed exercises with hypopnoeas and apnoeas indistinctively considered
as events
T1 NA NA 100 99
T2 NA NA 100 81.4
T3 96.7 66.3 99 87.5
T4 100 64.6 99.7 87.9
T5 99.2 59.2 99.2 95.1
T6 NA NA 100 89.8
T7 99 64.4 97 93.4
Total 99.2 62.8 99.5 90.5
Exercise
TP TN FC FP FN
WADD SOMNO WADD SOMNO WADD SOMNO WADD SOMNO WADD SOMNO
(C) Summary of classification of the different epochs
T1 0 0 380 376 0 0 0 4 0 0
T2 0 0 360 293 0 0 0 67 0 0
T3 89 61 285 252 2 26 3 36 3 31
T4 356 230 363 320 4 92 1 44 0 126
T5 357 213 365 350 0 100 3 18 3 147
T6 0 0 400 359 0 0 0 41 0 0
T7 189 123 191 184 9 31 6 13 2 68
Total 991 627 2344 2134 15 249 13 223 8 372
Part (a) of the table shows the sensitivity and specificity not considering hypopnoeas as events (ie, all hypopnoeas are considered breathing).
Based on this all FCs (apnoeas wrongly classified as hypopnoeas) are considered FNs; and all FPs hypopnoeas are considered TNs. Part
(b) shows the sensitivity and specificity considering apnoea and hypopnoea as indistinctive events. Based on this all FC are reclassified as
TPs; and all FP hypopnoeas are FPs. Part (c) details the number of epochs corresponding to a particular classification.
FC, false classification; FN, false negative; FP, false positive; TN, true negative (breathing); TP, true positive (apnoea); WADD, wearable
apnoea detection device.
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superior to the portable polysomnography system
(SOMNO) during overnight recordings.
WADD had 97.7–99.2% sensitivity to detect instructed
apnoeas and 88.6–99.1% for 10 s spontaneous apnoeas
during natural sleep, with similar performance in con-
trols and patients. The WADD also detected all apnoeas
over 30 s and there were only 3 over 30 s false positives.
For short apnoeas, in most cases, disagreement between
the clinician scorer and the WADD were caused by the
WADD identifying as apnoea epochs that the expert clas-
siﬁed as hypopnoeas.
As expected, the WADD performance was not as good
when apnoeas and hypopnoeas were considered together
(minimum sensitivity 77.1%).This is not surprising since
the WADD was designed to identify apnoea, not hypop-
noeas and the latter were detected from the transmitted
signal that had already been preprocessed for apnoea
detection. From the table, it can be observed that the
degradation of performance was more evident in the con-
trols because the controls had a large number of shorter
hypopnoeas (under 22.5 s), which the WADD did not
detect properly. In the patients, who often demonstrated
apnoeas, the hypopnoea events were longer and these
were detected by the WADD. Although the lower
sensitivity in hypopnoea detection might in principle
seem problematic if the WADD were to be used in the
context of sleep apnoea diagnosis (hypopnoeas are very
common events in sleep laboratories), it is worth noting
that: (1) there is no other reported automatic system that
gets anywhere close to this with similar speciﬁcity and
apnoea detection performance; (2) the variations
between different sleep laboratories due to the non-
uniform deﬁnition of hypopnoeas already leads to much
larger diagnostic variations than the limitation in sensitiv-
ity of the WADD35–37; and (3) assuming the worse case
scenario for the WADD, being that a patient only had
hypopnoeas throughout the night, this reduced sensitiv-
ity would be a problem that would translate to non-
diagnosis of sleep apnoea for patients who with 100%
sensitivity would have had a sleep apnoea hypopnoea
index (AHI) between 5 and 6 (ie, very mild cases of sleep
apnoea). Patients with no sleep apnoea, moderate
sleep apnoea, severe sleep apnoea and those with mild
sleep apnoea with AHI between 6 and 15 would have
been rightly diagnosed.
The median difference between the WADD calculated
AHI and the one obtained by the gold standard was
0 (average=0.7).
Figure 2 Illustration of the
SOMNO and wearable apnoea
detection device (WADD) output
signals showing an apnoea
event: (top) raw signals from the
different SOMNO sensors,
(middle) processed WADD signal,
(bottom) WADD output signal.
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SOMNO performance
The automatic analysis of the SOMNO apparatus, a
Food and Drug Administration (FDA) approved and
clinically accepted system, based on assessing apnoea
from a variety of different sensors, signiﬁcantly differed
from that of the expert marker, with an average sensitiv-
ity value of around 14%. The results obtained from the
instructed apnoeas tests also showed that even in the
absence of artefacts, apnoeas were not well detected by
the SOMNO system, with an average sensitivity of 37.8%.
This demonstrates the need for caution if relying on
current automated assessment methods for diagnosing
apnoea. While performance might be improved by opti-
mising parameters for individual patients, this is not
practical for single overnight recordings or use as an
alerting monitor. The WADD does not require any par-
ameter optimisation or participant speciﬁc calibration.
The SOMNO system performance improved in the
event of indistinct classiﬁcation of apnoeas and hypop-
noeas, but was still poor compared with the clinician
scorer (54% sensitivity). This sensitivity was at the cost of
reduced speciﬁcity: for every true hypopnoea detected
there were approximately four false detections. Overall,
the performance of the WADD in hypopnoea/apnoea
combined detection was signiﬁcantly better than the
SOMNO, in sensitivity (77.1% vs 54% if considering the
clinician scorer as a gold standard, and 84.1% vs 57.8%
otherwise), but also in speciﬁcity, as the WADD only
detected one false hypopnoea epoch for every four true
events.
Limitations and future improvements
The study described in this paper is a small pilot study
and hence further comprehensive clinical evaluation of
the technology will be necessary before it can be used.
The size of the study was, however, adequate to
assess the potential of the technology; to determine
whether the initial performance results in controlled
conditions were equivalent to those obtained in real
scenarios; and to inform a clinical trial. Based on these
positive results it is expected that a fully powered clinical
trial, focused on diagnosis rather than on individual
event identiﬁcation, will follow in the future.
Table 2 Summary of performance for the WADD, SOMNO and clinician scorer systems for detection of apnoea and
hypopnoea in 10 s epochs of overnight recordings
SOMNO
sensitivity
WADD
sensitivity
Clinician
sensitivity
SOMNO
specificity
WADD
specificity
Clinician
specificity
Apnoea detection (% sensitivity and specificity)
Controls 47.1 97.1 94.1 99.3 99.8 100
(95% CI) (30.3 to 63.8) (91.4 to 100) (86.2 to 100) (99.2 to 99.3) (99.7/99.8) (100 to 100)
Patients 14.7 99.4 98.1 99.5 99.5 99.9
(95% CI) (10.8 to 18.7) (98.5 to 100) (96.6 to 99.6) (99.5 to 99.6) (99.4 to 99.6) (99.8 to 99.9)
All 17.9 99.1 97.7 99.4 99.7 99.9
(95% CI) (13.9 to 22.0) (98.2/100) (96.1 to 99.3) (99.3 to 99.4) (99.6 to 99.7) (99.9 to 100)
Apnoea and hypopnoea combined detection (%)
Controls 87.8 58.1 94.6 98.6 99.7 100
(95% CI) (80.4 to 95.3) (46.9 to 69.4) (89.4 to 99.8) (98.5 to 98.7) (99.6 to 99.7) (100 to 100)
Patients 53.3 88.2 98.8 97.9 99.5 99.8
(95% CI) (48.9 to 57.8) (85.4 to 91.1) (97.8 to 99.8) (97.7 to 98.1) (99.4 to 99.6) (99.8 to 99.9)
All 57.8 84.1 98.2 98.4 99.5 99.9
(95% CI) (53.8 to 61.9) (81.1 to 87.1) (97.2 to 99.3) (98.3 to 98.5) (99.5 to 99.6) (99.9 to 100)
SOMNO sensitivity WADD sensitivity SOMNO specificity WADD specificity
Apnoea detection with the clinician scorer as gold standard reference (%)
Controls 38.9 86.1 99.2 99.7
(95% CI) (23.0 to 54.8) (74.8 to 97.4) (99.1 to 99.3) (99.7 to 99.8)
Patients 11.7 88.9 99.5 99.4
(95% CI) (8.3 to 15.1) (85.6 to 92.2) (99.4 to 99.6) (99.3 to 99.5)
All 14.3 88.6 99.3 99.6
(95% CI) (10.8 to 17.8) (85.4 to 91.8) (99.2 to 99.4) (99.6 to 99.7)
Apnoea and hypopnoea combined detection with clinician scorer as gold standard (%)
Controls 86.3 54.8 98.6 99.6
(95% CI) (63/73) (40/73) (41 539/42 139) (41 987/42 139)
Patients 49.6 80.1 98.4 100
(95% CI) (45.4 to 53.8) (75.2 to 82.1) (98.2 to 98.6) (99.9 to 100)
All 54.0 77.1 98.5 99.7
(95% CI) (50.0 to 57.9) (73.8 to 80.5) (98.4 to 98.6) (99.7 to 99.8)
WADD, wearable apnoea detection device.
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The calculation of the sensitivity and speciﬁcity has
assumed that all apnoea events were independent, which
for some might not be completely correct. If the data had
not been pooled, and taking the expert marker as the
gold-standard, in 67% of the participants the individual
apnoea detection sensitivity was 100%. In 77% it was over
90%. In the remaining cases, the drop in sensitivity corre-
sponded always to just one non-detected apnoea shorter
than 15 s in the 6 h night, which is clinically insigniﬁcant.
The average from the individual sensitivities was 2%
higher than the value obtained pooling the data. In
terms of speciﬁcity 90% of the participants had values
higher than 99%. Two-thirds of them were over 99.9%.
The average of the individual speciﬁcities was identical to
the speciﬁcity obtained pooling the data.
A different statistical analysis, possibly comparing
pooled with non-pooled data, will be the subject of
investigation when the technology undergoes a larger
clinical trial.
The WADD is obviously no substitute to a full night
study in a sleep clinic, since it does not provide all the
information that a full polysomnography system would.
There are advantages and disadvantages to this device
with respect to full polysomnography. The WADD can be
used to determine the AHI, which is used in sleep
apnoea diagnosis to ascertain whether a patient has
sleep apnoea and to score the severity of the condition.
The WADD’s main advantage is that it can be used for
home assessment or monitoring, and from that point of
view it is clearly superior to any of the other existing
devices (highly resilient to artefacts, very easy to attach
and durable in position, low cost, much more comfort-
able and accurate). Considering the restricted resources
for sleep clinic referral this device could be a very useful
tool to determine, at very low cost, who should be
referred to a specialist centre for full polysomnography.
The disadvantage is that there are other parameters that
could be used for extra-assessment that the device does
not measure, such as microarousal or full cardiac activ-
ity. Furthermore, the WADD does not allow assessment
of the hypoxic load or autonomic activation and there-
fore impacts the cardiovascular or stroke risk associated
with OSA syndrome.
The WADD device used in the current study relied on
wireless transmission to a PC. However, changing the PC
to a dedicated mobile phone sized receiver poses no
technological challenge. A subsequent version that is
being developed is smaller (2.4 by 2.4 by 1.2 cm, weigh-
ing 7.5 g) and can operate continuously on hearing aid
batteries for over 48 h. It has a separate dedicated
receiver of comparable size to a mobile phone, which
can be located up to 10 m from the participant.
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